Značka FORSYNZIG, založená v 2012 (United States), z 496 sesterských značek a 17478 konkurenčních značek. Značku FORSYNZIG vlastní BRISTOL-MYERS SQUIBB COMPANY, společnost kótovaná na burze v New York. FORSYNZIG patří do odvětví Výrobci léků činnosti.
Nákup akcie BRISTOL-MYERS SQUIBB COMPANY s
(0% provize a zlomkové podíly)
Váš kapitál podléhá riziku. Platí se další poplatky. Pro více informací navštivte etoro.com/trading/fees.
Ostatní značky
BRISTOL-MYERS SQUIBB COMPANY
-
A
- Amylin Pharmaceuticals
- AHEFCI
- ALIKLUVE
- ADVOREY
- AUREXIS
- AZENMI
- AKAZEP
- AEGEAN - Assessment of an Education and Guidance program for Eliquis Adherence in Non-valvular atrial fibrillation
- AVENUE: An Investigation and Understanding
- ACTIVJEX
- A-CLICK
- ADVANCEGRIP
- APEXAGARD
- AVEMRY
- AMNIQUIS
- AVATREUM
- ADVANCING IMMUNOTHERAPY in ONCOLOGY
- APEXIGUARD
- APEXAGUARD
- AVAXATAP
- ADNEXUS
- ABLIXTO
- APERFIT
- ADNECTIN
- ANGIOCEPT
- AGREE
- AVERROES
- APPRAISE APixaban for PRevention of Acute Ischemic Safety Events
- APixabanforPReventionofAcuteIschemicSafetyEvents
- APROPOS
- ARISTOTLE
- APPEAR
- AWAKEN
- ALSAXLO
- ARRIVE - ABATACEPT RESEARCHED IN RHEUMATOID ARTHRITIS PATIENTS WITH AN INADEQUATE ANTI-TNF RESPONSE TO VALIDATE EFFECTIVENESS
- ARPIQUA
- ARZUVAD
- AIM B Avareness Intervention and Management of Chronic Hepatitis B
- AXECTITUDE
- APLURIZE
- ALERTUM
- ASIDE: A PHASE IIIB, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ABATACEPT ADMINISTERED SUBCUTANEOUSLY AND INTRAVENOUSLY IN
- ADNEXUS THERAPEUTICS
- ALBITAL
- ACTOL
-
B
- BEQSTIAT
- BEXLAMDA
- BOKIQSA
- BECAUSE EACH ENDPOINT COUNTS
- Be Melanoma Smart
- BECLICK
- BILTIMET
- BRIPALO
- BRIVADEP
- BRIPOLO
- BRAPOLO
- BRIVTAGA
- BRIVTAGNA
- BAMBROVA
- BRAPOLLO
- BRIPOLLO
- BRABANTIV
- BRAPIXA
- BYTIFIC
- BALTARC
- BELOW
- Bristol-Myers Squibb Together we can prevail.
- BREGLIV
- BMS
- BMS BRISTOL-MYERS SQUIBB COMPANY
- BMS IRBESARTAN
- BANREVLA
- BELLAQUIP
- BRELCAPA
- BELTAPTA
- BRISTOL-MYERS SQUIBB TRANSFER DEVICE
- BMS VIROLOGY
- BRONCOCLAR
-
C
- ConvaTec Divestiture
- Cardioxyl Pharmaceuticals
- CMPASS-EU
- COBLIXRA
- CLATAZEV
- CEVRIEP
- CHECKMATE
- CIMMKEY
- CESVUNO
- CESVONO
- CHOOSE TO MAKE A DIFFERENCE
- CONTINUUM OF CARE
- CML THERAPY
- CUSTOMERS @ CENTER
- CLICKJECT
- COMFICLIQ
- COMFICLICK
- CML SCORING TOOL
- CONFIHOLD
- CONFIGLIDE
- CIPRALAN
- CARBOPHOS
- CAPLET
- CO-EFFERALGAN
- CEFALOJECT
- CEFALGAN
- CHOLOVERNIL
- CAL-C-TOSE
- Carvasept
-
D
- DuPont Pharmaceuticals
- DRIVIXTI
- DAKMELA
- DURLAMDA
- DACLIRCO
- DACLERAD
- DEMVEP
- DASCOVERY
- DOTHEMATOLOGY
- DUOGYZA
- DUOGYZE
- DALRADCO
- DALRADCA
- DUOGLYZE
- DAPAGLEZE
- DAPLICISE
- DURMABA
- DEFINE
- DELBAVA
- DURMABRA
- DURSPONSE
- DARCELBA
- DISCOVERING THE NEXT FUTURE
- DEMONSTRate: Drug Evalutation in Melanoma: ONcology STudy and Research of Ipilimumab
- Dermster OBERLIN
- DEXFLUID
- DATUB
- DEXIR
- DONORMYL
- DECTINIA
- Dubatol
- DIFEGASTRYL
-
E
- EMPLICITI
- EBLETEG
- ELZESKI
- ETOTUZE
- ENODUB
- EVOTAZ
- EVEBLY
- ETINZUE
- EMKELOS
- ELZITUDE
- epiQuid?
- E-ALL OF THE ABOVE
- EPIQUID
- ELOQUENT
- EBLICIMET
- EBYONT
- ERGOEASE
- EASYDELIVER
- ERGOGLIDE
- EASYGRASP
- ELAQUIS
- EVEMRY
- EXPANSE
- ECEVLI
- Enlite The Essential Breast Cancer Resource
- ERZELBA
- EFFERALGAN
- EFFERFRESCO
- EFFERALGIN
- Eldophyllin
- ENFALAC
-
F
-
G
-
H
-
I
-
J
-
K
-
L
-
M
-
N
-
O
- OBREFCO
- ORKEPA
- OPDIVO
- OPD1VO
- OPDETA
- OPDYTA
- OTAC ONCOLOGY TUMOR ADVISORY COUNCIL
- OPTI-MONITOR Knowledge and tools for optimal care
- OPTI-MONITOR
- ORZINDO
- ORENCIA SIMPLEGRIP
- ORENCIA SECUREGRIP
- ORENCIA ADVANCEGRIP
- ORENCIA ERGOEASE
- ORENCIA SIMPLEGLIDE
- ORENCIA EASYGRASP
- ORENCIA CONFIHOLD
- ORENCIA CONFIGLIDE
- ORENCIA TAILORGRIP
- ORENCIA EASYDELIVER
- ONOSERAMET
- ORBRODA
- ONGLAMET
- ONGLIMET
- ONGLYZA PLUS MET
- ONGLYZA + MET
- ONGLYMET
- ORTUNIT
- ORENCIA ZENGRIP
- ORENCIA SURESPRING
- ORENCIA SWIFTDOSE
- ORENCIA GLISSADER
- ORENCIA FEATHERJET
- ORENCIA FEATHERJECT
- ORENCIA FEATHERFIT
- ORENCIA COMFORTDOSE
- ORENCIA DEXIGN
- ORENCIA COMFORTSHOT
- ORENCIA SPRINGJECT
- ORENCIA DIRECTJECT
- ORENCIA EFFORTEASE
- ORENCIA
- Oncology Innovation Interchange
- ONGLIP
- ONGLIPA
- ORENCIA See what's possible
- ORZIPTA
- OMNORTA
- ORSPECTA
- ORZULTI
- OMAXIT
-
P
-
Q
-
R
-
S
- SIMPLISERT
- SLAMUNITI
- SUZEMO
- SUNVEPZI
- SIGDUO
- SIMPLEGRIP
- SIMPLEGLIDE
- SAXXAVIBE
- SAXAVIBE
- SOGLUXOS
- SAXAMETRA
- SAXXIVIBE
- SAXIVIBE
- STANDING STRONG AGAINST RESISTANCE
- STRENTARGA
- SYNXABA
- STRENTAARGA
- SABLIXTO
- SAXIMETRA
- STRENTUBA
- SPRYZEL
- STRENCARA
- SPRIZEL
- STRENKARA
- SPRICEL
- SPRICELL
- SEE WHAT'S POSSIBLE
- SEVER'ALGIA
- SOLUPSA
-
T
-
U
-
V
-
W
-
X
-
Y
-
Z
